Urologie retweeted
Semi-Live 2022 GLOBAL (March 2-5, 2022): Join wherever you are!
State of the Art in Urologic Surgery: View, discuss, reflect, contemplate, chat and earn CME's! Limitless due to opportunity!
Program and Registration: semi-live.org
youtube.com/watch?v=KGmR6WO-…
Semi-Live 2022 GLOBAL (March 2-5, 2022): Join wherever you are!
State of the Art in Urologic Surgery: View, discuss, reflect, contemplate, chat and earn CME's! Limitless due to opportunity!
Program and Registration: semi-live.org
youtube.com/watch?v=KGmR6WO-…
Urologie retweeted
Invitation to “Semi-Live 2022” in Heidelberg!
Registration is open! Early bird discount until December 15, 2021.
All info here: semi-live.org/
State-of-the-art staging of high risk prostate cancer for subsequent local therapy: replacement of CT and bone scan by PSMA-PET.
thelancet.com/journals/lance…
Radiotherapy (RT) following radical prostatectomy: early salvage RT (PSA 0.2 ng/ml) vs.adjuvant RT reduces over-treatment by 50% with concomitant reduction of functional morbidities without compromising oncological safety.
thelancet.com/journals/lanon…
"Telephone": Multilateral Communication Management in Clinical Medicine
nejm.org/doi/full/10.1056/NE…
Epigenetics of the fetal prostate and their association with metastatic prostate cancer
nejm.org/doi/full/10.1056/NE…
RAVES or the end of adjuvant radiotherapy in high-risk prostate cancer: early salvage radiotherapy +/- equally effective if delivered at a PSA of < / = 0.2.
PS: Indicate PSMA-PET in BCR!
thelancet.com/pdfs/journals/…
TREXIT?: Needle track seeding of prostate cancer after transrectal prostate biopsy.
reader.elsevier.com/reader/s…
RPx With vs. Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk PCa improved:
event-free (e.g. death, progression, additional treatment), metastatic free, & overall survival.
Did not improve 3-year biochemical progression-free survival.
ascopubs.org/doi/pdf/10.1200…
Die Urologie in Zeiten von Corona | Mit Prof. Dr. Markus Hohenfellner | ... youtu.be/z-ywJvu1ruo via @YouTube
Precision oncology beats high-end standard care in Prostate Cancer:
nejm.org/doi/full/10.1056/NE…
DARULTAMIDE 4 NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:
=> reduces the risk of death by 30%
=> vs. placebo comparable adverse events
nejm.org/do/10.1056/NEJMdo00…
Similar pathways of compromized immunology in critical virus infections vs. critical cancers: a possible role of T cell - increased PD-1 expression. With a perspective of new indications for Checkpoint Inhibitors?
Sattler, Kotsch et al. (Charité 2020) jci.org/articles/view/140965
Beyond (whole) genome sequencing: epigenetic drivers and early associated therapies of cancer
nejm.org/doi/full/10.1056/NE…
A day in the Life: When being wrong as a doctor, is the best outcome for the patient.
nejm.org/doi/full/10.1056/NE…



